Related Experiment Video

Updated: May 13, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Pentoxifylline treatment for protecting diabetic retinopaty in children with type 1 diabetes

Murat Baykara1, Mehmet Emre Atabek, Beray Selver Eklioglu

  • 1Department of Radiology, Erciyes University, Kayseri, Turkey.

Journal of Pediatric Endocrinology & Metabolism : JPEM
|March 5, 2013
PubMed

Insights

Oral pentoxifylline improved retinal microvascular hemodynamics in children with type 1 diabetes. This treatment may offer protection against diabetic retinopathy and atherosclerosis risk factors.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Vascular Biology

Background:

  • Type 1 diabetes mellitus (DM) poses risks for microvascular complications, including diabetic retinopathy.
  • Retinal microvascular dysfunction is a hallmark of diabetic complications.
  • Assessing interventions to improve retinal hemodynamics in pediatric diabetes is crucial.

Purpose of the Study:

  • To evaluate the effect of oral pentoxifylline (PTX) on retinal microvascular hemodynamics in children with type 1 DM.
  • To determine if PTX administration can alter key hemodynamic parameters in the central retinal artery (CRA).

Main Methods:

  • A randomized controlled trial involving 56 children with type 1 DM.
  • Non-invasive ultrasonographic measurements of CRA pulsatility index (PI), resistivity index (RI), peak systolic velocity (PSV), and end diastolic velocity (EDV).
  • Comparison of hemodynamic changes after 6 months of pentoxifylline treatment versus a placebo control group.

Main Results:

  • Pentoxifylline significantly reduced the pulsatility index (PI) in the central retinal artery (p=0.01).
  • While RI, PSV, and EDV showed a trend towards reduction, these changes were not statistically significant.
  • Pentoxifylline treatment also led to reduced blood pressure, microalbuminuria, and improved HDL levels.

Conclusions:

  • Pentoxifylline demonstrates potential protective effects against diabetic retinopathy in type 1 diabetes.
  • The drug may modulate key risk factors associated with atherosclerosis in this patient population.
  • Further research is warranted to confirm these findings and explore therapeutic applications.
Abstract

More Related Videos

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tg(fli:EGFP) Zebrafish Retinal Vasculature10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tg(fli:EGFP) Zebrafish Retinal Vasculature

Published on: December 26, 2017

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...